ReviewCureus2025
Association Between the High Stress Hyperglycemia Ratio and Outcomes of Mechanical Thrombectomy: A Systematic Review and Meta-Analysis.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stroke is a major cause of global death and disability, with mechanical thrombectomy (MT) as the gold standard treatment for large vessel occlusion. The stress hyperglycemia ratio (SHR), which accounts for long-term glycemic control via glycated hemoglobin (HbA1c), is a promising predictor of stroke outcomes. However, its prognostic value in acute ischemic stroke (AIS) patients treated with MT has not been systematically evaluated. We conducted a meta-analysis to assess the association between SHR and outcomes after MT. PubMed, Embase, Cochrane Library, and Google Scholar were searched. Analyzed outcomes included functional outcomes, mortality, early neurological deterioration (END), and symptomatic intracranial hemorrhage (sICH). Data were pooled using random-effects models, with heterogeneity assessed by I² statistics. High SHR was significantly associated with increased 90-day poor outcomes (OR=2.98; 95% CI: 1.89-4.71; p<0.0001), low 90-day good outcomes (OR=0.43; 95% CI: 0.32-0.59; p<0.0001), increased 90-day mortality (OR=2.06; 95% CI: 1.37-3.11; p=0.0005), higher risk of END (OR=6.27; 95% CI: 3.22-12.24; p<0.0001), and sICH (OR=2.53; 95% CI: 1.73-3.70; p<0.0001). Elevated SHR predicts poor outcomes, higher mortality, and more complications in AIS patients undergoing MT, highlighting its importance in stroke management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.